(Q42386107)

29 October 2017

JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines (English)

1 reference

29 October 2017

1 reference

acute erythroid leukemia

1 reference

Wanke Zhao

1

1 reference

29 October 2017

Yanhong Du

2

1 reference

29 October 2017

Wanting Tina Ho

3

1 reference

29 October 2017

Xueqi Fu

4

1 reference

29 October 2017

Zhizhuang Joe Zhao

5

1 reference

29 October 2017

21 June 2012

1 reference

Experimental Hematology & Oncology

29 October 2017

1 reference

29 October 2017

1

1 reference

29 October 2017

1

1 reference

29 October 2017

15

1 reference

Creative Commons Attribution 2.0 Generic

29 October 2017

start time

21 June 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Development of a highly sensitive method for detection of JAK2V617F

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

Cancer and ageing: convergent and divergent mechanisms

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

Identification of an acquired JAK2 mutation in polycythemia vera

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

p53: guardian AND suppressor of longevity?

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

HEL Cells: A New Human Erythroleukemia Cell Line with Spontaneous and Induced Globin Expression

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3514099

The price of tumour suppression?

16 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F2162-3619-1-15

Delayed ageing through damage protection by the Arf/p53 pathway

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F2162-3619-1-15

Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis

21 January 2018

1 reference

12 December 2020

Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia

1 reference

12 December 2020

20 years studying p53 functions in genetically engineered mice

1 reference

12 December 2020

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

1 reference

12 December 2020

Identifiers

DOI

10.1186/2162-3619-1-15

1 reference

Dimensions Publication ID

29 October 2017

0 references

1 reference

29 October 2017

PubMed publication ID

23210734

1 reference